Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

ANVS

A

Annovis Bio, Inc. (ANVS)

NYQ – Цена в реальном времени. Валюта: USD

2.28

-0.11 (-4.60%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that Maria Maccecchini, Ph.D.

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including in ApoE4 carriers Phase 2/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a new publication titled “Buntanetap treatment in mild to moderate Alzheimer's disease: phase 2/3 study” in a peer-reviewed journal Nature NPJ Dementia.

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.50 per share of common stock, will be exercisable commencing six months following the issue date and will expire five years and 6 months after the date of issuance.

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No.

Annovis Publishes Historical Review of Buntanetap in The Scientist

Annovis Publishes Historical Review of Buntanetap in The Scientist

MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled “Buntanetap: From Execution Poison to Potential Alzheimer's Disease Drug”, examining the history of discovery and development of buntanetap, the Company's lead drug candidate.

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM , a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson's study.

Видео

No Data

There is no data to display

Пресс-релизы

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including in ApoE4 carriers Phase 2/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a new publication titled “Buntanetap treatment in mild to moderate Alzheimer's disease: phase 2/3 study” in a peer-reviewed journal Nature NPJ Dementia.

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.50 per share of common stock, will be exercisable commencing six months following the issue date and will expire five years and 6 months after the date of issuance.

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No.